Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

BGB-3111, a Highly Specific BTK Inhibitor, Is Well Tolerated and Highly Active in Chinese Patients with Relapsed/Refractory B-Cell Malignancies: Initial Report of a Phase 1 Trial in China

Jun Zhu, BS, Jianyong Li, MD, Jianfeng Zhou, Yuqin Song, MD, Junyuan Qi, Wei Xu, Dengju Li, MD, Mingyuan Sun, Ling Xue, PhD, Liudi Yang, Yinwei Zhang, Lai Wang, PhD, Jane Huang, MD, Shibao Feng, PhD, Lugui Qiu, MD

Blood (2017) 130 (Supplement 1): 5347.

https://doi.org/10.1182/blood.V130.Suppl_1.5347.5347

Published: 2017

Journal Articles

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin's Lymphoma

Constantine S. Tam, MBBS, MD FRACP, FRCPA, David Simpson, MBChB, Stephen Opat, FRACP, FRCPA, Won Seog Kim, MD, Ph. D., Michael Wang, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Patrick B Johnston, MD PhD, Javier Munoz, MD, Won-Sik Lee, MD, Paula Marlton, MBBS, David Gottlieb, MBBS, MD FRACP, FRCPA, Lai Wang, PhD, Jane Huang, MD, James Hilger, Ling Xue, PhD, Sunhee Ro, PhD, Judith Trotman, FRACP

Blood (2017) 130 (Supplement 1): 152.

https://doi.org/10.1182/blood.V130.Suppl_1.152.152

Published: 2017

Journal Articles

High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study

Constantine S. Tam, MBBS, Judith Trotman, MBChB, Stephen Opat, MD, Paula Marlton, MBBS, Gavin Cull, MBBS DM FRACP FRCPA, David Simpson, MBChB, FRACP, FRCPA, Matthew Ku, MBBS, David Ritchie, MD PhD, Emma Verner, FRACP, FRCPA, MBBS, Sumita Ratnasingam, MBBS, Mary Ann Anderson, MBBS, Peter Wood, MD FRACP, FRCPA, MBBS, Mark Kirschbaum, MD, Lai Wang, PhD, Ling Xue, Jianxin Yang, Eric Hedrick, John F Seymour, Andrew W. Roberts

Blood (2016) 128 (22): 1216.

https://doi.org/10.1182/blood.V128.22.1216.1216

Published: 2016

Journal Articles

Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Constantine S. Tam, MBBS, Stephen Opat, MD, Gavin Cull, MBBS DM FRACP FRCPA, Judith Trotman, MBChB, David Gottlieb, MBBS MD FRACP FRCPA, David Simpson, MBChB, FRACP, FRCPA, Paula Marlton, MBBS, Mary Ann Anderson, MBBS, Matthew Ku, MBBS, David Ritchie, MD PhD, Sumita Ratnasingam, MBBS, Bradley Augustson, Mark Kirschbaum, MD, Lai Wang, PhD, Ling Xue, Jianxin Yang, Eric Hedrick, John F Seymour, Andrew W. Roberts

Blood (2016) 128 (22): 642.

https://doi.org/10.1182/blood.V128.22.642.642

Published: 2016

Journal Articles

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Constantine Tam, MBBS, MD, Andrew P Grigg, MBBS MD, Stephen Opat, MBBS, Matthew Ku, MBBS, Michael Gilbertson, MBBS, Mary Ann Anderson, MBBS, John F. Seymour, MBBS, PhD, David S. Ritchie, MDPhD, Carmen Dicorleto, Belinda Dimovski, Eric Hedrick, Jianxin Yang, Lai Wang, PhD, Lusong Luo, Ling Xue, Andrew W. Roberts, MBBS, PhD

Blood (2015) 126 (23): 832.

https://doi.org/10.1182/blood.V126.23.832.832

Published: 2015

Journal Articles

Combination of Ibrutinib and BCL-2 or SYK Inhibitors in Ibrutinib Resistant ABC-Subtype of Diffuse Large B-Cell Lymphoma

Hsu-Ping Kuo, Richard Crowley, Ling Xue, Karl J. Schweighofer, Leo WK. Cheung, Sidney Hsieh, Karl Eckert, BA, Matthias Versele, Betty Y. Chang

Blood (2014) 124 (21): 505.

https://doi.org/10.1182/blood.V124.21.505.505

Published: 2014

Journal Articles

Premalignant PTEN-deficient thymocytes activate microRNAs miR-146a and miR-146b as a cellular defense against malignant transformation

Megan L. Burger, Ling Xue, Yuefang Sun, Chulho Kang, Astar Winoto

Blood (2014) 123 (26): 4089–4100.

https://doi.org/10.1182/blood-2013-11-539411

Published: 2014

Includes: Supplemental data

Journal Articles

Population Pharmacokinetics Study of Tacrolimus in Chinese Hematopoietic Cell Transplant Patients.

Ling Xue, Jian-Zhong Rui, Yan Zhang, Li-Yan Miao

Blood (2009) 114 (22): 4668.

https://doi.org/10.1182/blood.V114.22.4668.4668

Published: 2009

NARROW

BGB-3111, a Highly Specific BTK Inhibitor, Is Well Tolerated and Highly Active in Chinese Patients with Relapsed/Refractory B-Cell Malignancies: Initial Report of a Phase 1 Trial in China

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin's Lymphoma

High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study

Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Combination of Ibrutinib and BCL-2 or SYK Inhibitors in Ibrutinib Resistant ABC-Subtype of Diffuse Large B-Cell Lymphoma

Premalignant PTEN-deficient thymocytes activate microRNAs miR-146a and miR-146b as a cellular defense against malignant transformation

Population Pharmacokinetics Study of Tacrolimus in Chinese Hematopoietic Cell Transplant Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only